Biotech Radar
Biotech Radar – $DFTX $ABSI $NVCT – June 24, 2026
Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
DFTXDefinium Therapeutics
ABSIAbsci Corporation
NVCTNuvectis Pharma
The June 24, 2026 biotech radar highlights three names moving on identifiable fundamental catalysts: Definium Therapeutics after positive Phase 3 depression data and an upsized equity offering, Absci after analyst coverage around its AI-driven pipeline, and Nuvectis Pharma after an ex-China licensing agreement with Haisco that adds two clinical-stage assets.
The prices and volumes below are an intraday snapshot from June 24, 2026 and can change quickly. The editorial point is not to chase the price, but to understand what kind of news is moving each stock, how solid the catalyst is, and what risk remains after the rally.
| Ticker | Company | Intraday move | Approx. price | Approx. market cap | Main catalyst |
|---|---|---|---|---|---|
| DFTX | Definium Therapeutics | +21.5% | $43.97 | $4.77B | DT120 ODT met the primary and key secondary endpoints in the Phase 3 Emerge study for MDD; upsized public offering of about $700M at $34 per share. |
| ABSI | Absci Corp | +23.5% | $9.15 | $1.40B | Leerink initiated at Outperform with a $12 target; Guggenheim raised its target to $15 from $10 on ABS-201 and the PRLR/AI pipeline. |
| NVCT | Nuvectis Pharma | +20.2% | $21.10 | $494M | Ex-China license from Haisco for NXP100, a Factor B inhibitor, and NXP200, a BRAF paradox-breaker inhibitor. |
DFTX
Definium Therapeutics, Inc.
+21.5%
$43.97 · Approx. market cap $4.77B · Approx. volume 6.8M
Catalyst: positive Phase 3 data for DT120 ODT in major depressive disorder
Verified primary catalyst
Definium announced that the Phase 3 Emerge study of DT120 ODT, lysergide tartrate in an orally disintegrating tablet, met its primary endpoint and all key secondary endpoints in major depressive disorder. The key figure is an 8.1-point placebo-adjusted difference on MADRS at Week 6, with p<0.0001.
MADRS Week 6
8.1 pts
Difference vs placebo
Endpoints
Met
Primary and key secondaries
Offering
$700M
Priced at $34/share
NDA path
Not yet
Regulatory package still needed
Why the market reaction was so strong
In biotech, a positive Phase 3 result carries far more weight than a promotional headline. Here the market is not just reacting to a press release; it is reassessing whether DT120 ODT could become a serious regulatory asset in a large psychiatric indication. The MADRS difference at Week 6 is large, statistically strong according to the company release, and comes in a field where even smaller improvements can materially change investor expectations.
The second part is financial. Definium first announced a proposed $500M public offering, and the market then saw an upsized offering of about $700M at $34 per share. Dilution is real and material, but the upsizing after the readout points to substantial institutional demand. That does not remove risk, but it helps explain why the stock is being treated as a clinical/commercial story rather than only a one-day speculative move.
Company context
Definium Therapeutics is the new name of Mind Medicine, MindMed, following the rebranding announced in January 2026. The company also communicated the Nasdaq ticker change to DFTX and framed the new identity as a move toward a late-stage psychiatry pipeline led by DT120 ODT. That matters for readers who still remember the name MNMD: this is not a completely new company, but a rebranded and repositioned version of the same clinical story.
Risks: the full data still need to be analyzed more deeply by the medical community, and the FDA path requires further steps. The $700M offering strengthens the balance sheet but increases the share count. DT120 also remains a complex psychiatric asset, with regulatory, commercial, clinical-infrastructure and physician-adoption risk.
ABSI
Absci Corporation
+23.5%
$9.15 · Approx. market cap $1.40B · Approx. volume 19.1M
Catalyst: analyst coverage on an AI-native pipeline still in early validation
Verified primary catalyst
Absci moved after a sequence of supportive analyst actions: Leerink initiated coverage with an Outperform rating and a $12 target, while Guggenheim raised its target to $15 from $10 while maintaining Buy. The market focus is ABS-201, an AI-designed anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Leerink
$12
Outperform initiation
Guggenheim
$15
From $10, Buy
Lead asset
ABS-201
Anti-PRLR antibody
Endometriosis
Q4 2026
Phase 2 expected
What Absci does
Absci is a biotech company focused on drug discovery and biologics development using generative models and a synthetic biology platform to design therapeutic candidates. For ABS-201, the company is targeting the prolactin receptor with a subcutaneous antibody designed for potentially infrequent dosing. Absci presents ABS-201 as a possible new mechanism for androgenetic alopecia and as a differentiated candidate for endometriosis, two areas with meaningful medical and commercial need.
The important distinction is that today’s rally is not based on newly released clinical efficacy data. It is based on analyst reassessment and attention around future catalysts: preliminary safety/tolerability and PK work, interim proof-of-concept data in AGA in the second half of 2026, and a planned Phase 2 start in endometriosis in the fourth quarter of 2026.
Why this is interesting, but different from DFTX
DFTX has just reported a Phase 3 readout. ABSI is still a validation story: the market is paying ahead for the possibility that the AI platform and ABS-201 program can produce convincing clinical signals. That makes the setup more speculative. If the data support safety, pharmacokinetics and a credible efficacy signal, the AI-biotech narrative could strengthen. If the data are weak or ambiguous, the valuation premium can compress quickly.
Risks: the catalyst is analyst-driven, not a new efficacy readout. ABS-201 remains early-stage, and clinical failure risk is materially high. AI-drug-discovery companies can receive high multiples during periods of enthusiasm, but the market tends to reprice them sharply when the platform does not produce convincing clinical data.
NVCT
Nuvectis Pharma, Inc.
+20.2%
$21.10 · Approx. market cap $494M · Approx. volume 268K
Catalyst: Haisco license adds two clinical-stage assets
Verified primary catalyst
Nuvectis announced a license agreement with Haisco Pharmaceutical Group for ex-China rights to two clinical-stage candidates: NXP100, a Factor B inhibitor for complement-mediated diseases, and NXP200, a BRAF paradox-breaker inhibitor for advanced cancers. The announcement shifts the company from a concentrated pipeline profile to a broader development story.
New asset 1
NXP100
Factor B inhibitor
New asset 2
NXP200
BRAF paradox-breaker
Upfront/near-term
Up to $40M
Payments to Haisco
Milestones
Up to $1.421B
Development, regulatory, commercial
What changes for Nuvectis
Before the agreement, Nuvectis was mainly read through NXP900, an oral oncology candidate inhibiting the SRC family of kinases, including SRC and YES1. With NXP100 and NXP200, the company adds one complement program and a second oncology program, creating a broader narrative and a pipeline that is potentially less dependent on a single asset.
NXP100 is relevant because complement is already a commercially validated area through drugs such as Soliris and follow-on products, but it remains competitive and regulatorily demanding. According to the company communication, two MAAs for NXP100 have been submitted to China’s NMPA and are under review. NXP200 is described as an oral, brain-penetrant, paradox-breaker BRAF inhibitor with potential use in BRAF-altered solid tumors, including CNS, colorectal cancer, melanoma and NSCLC.
The deal economics
The key detail is the transaction structure: Nuvectis receives worldwide ex-China rights, while Haisco also retains rights for NXP100 in India and certain Southeast Asian territories. Haisco may receive up to $40M in upfront and near-term payments, up to $1.421B in additional development, regulatory and commercial milestones, and tiered royalties on future net sales. The agreement is also subject to financing conditions that Nuvectis must meet to ensure sufficient capital for development of the licensed products.
Risks: volume remains much lower than DFTX and ABSI, so the move can be more volatile. The assets come from China-based development and need to be integrated into a credible FDA/EMA strategy. The headline milestones are potential payments, not cash received today; real value will depend on data, regulatory execution, financing and clinical development.
Disclaimer: This content is published for educational and informational purposes only by Merlintrader.com. It does not constitute financial advice, an investment recommendation, a solicitation to buy or sell securities, or personalized investment research. Market data are intraday and may change quickly.
Important notice: This content is not personalized investment research and does not consider any reader’s objectives, financial situation or risk tolerance. Consult a qualified professional before making any investment decision. Full disclosure: merlintrader.com/disclaimer.
SEC-style notice: This content is for informational and educational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Merlintrader is not a registered investment adviser.
Biotech Catalyst Calendar – Merlintrader
Follow upcoming U.S. biotech catalysts, including PDUFA dates, Phase 2/3 clinical data and FDA decisions.
Open the Biotech Catalyst CalendarRelated Merlintrader pages
Get updates in real time
Join the Merlintrader Telegram channel for new catalyst updates and research as it goes live.
Join @merlintraderpub_com on Telegram